A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Thépot, Sylvain, Ben Abdelali, Raouf, Chevret, Sylvie, Renneville, Aline, Beyne-Rauzy, Odile, Prébet, Thomas, Park, Sophie, Stamatoullas, Aspasia, Guerci-Bresler, Agnes, Cheze, Stéphane, Tertian, Gérard, Choufi, Bachra, Legros, Laurence, Bastié, Jean Noel, Delaunay, Jacques, Chaury, Marie Pierre, Sanhes, Laurence, Wattel, Eric, Dreyfus, Francois, Vey, Norbert, Chermat, Fatiha, Preudhomme, Claude, Fenaux, Pierre, Gardin, Claude
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2016
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967570/
https://ncbi.nlm.nih.gov/pubmed/27229713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.140988
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars